Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a $31 price target.
February 02, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterated a Buy rating on Nurix Therapeutics and maintained a $31 price target.
The reiteration of a Buy rating and maintenance of a $31 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could positively impact Nurix Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100